Lindsay Hartland Neuromodulation Executive Sear
Post# of 8719

Neuromodulation Executive Search & Commercialization Partner | Paving the Path for NeuroTech Start-ups | Board Advisor | Hanison Green Founder | Touchdown Neurotech Co-founder | RFC & RMC Co-founder | Changer of Lives
Henley Business School Hanison Green Ltd
London, England, United Kingdom
The rise of non-invasive #neuromodulation is no longer a niche story; it’s becoming a market reality.
The global non-invasive neurostim devices market is set to double from $3.4B last year to $7.1B in 2034 at 7.5% CAGR.
The world is waking up to the power of drug-free, surgery-free solutions for some of our most challenging neurological and psychiatric conditions such as #chronicpain #depression & #anxiety #epilepsy #migraine and movement & cognitive disorders.
Growth drivers include:
• The wearable revolution: portable, consumer-friendly devices bringing brain health into the home.
• AI + digital platforms enabling personalization and app-based monitoring.
• Strong clinical evidence especially in pain and psychiatric care.
• Major investment flowing into mental health tech and brain-computer interfaces.
North America of course leads market share with 43% and Europe with 30%, and APAC is seemingly the fastest-growing with a CAGR of 8.9%.
And while TENS dominates in consumer use, it’s TMS & tDCS that are scaling fastest, particularly in mental health and cognitive therapies.
Reimbursement allowing, adoption of non-invasive neuromodulation should continue to outperform the market as it allows a shift away from pills and invasive procedures, toward accessible, personalized neurotherapies that can transform patient outcomes worldwide.
Is non-invasive set to dominate the future of Neuromod?
About
I partner with neuromodulation device company founders, leaders, and investors across the US & Europe; helping them grow and achieve their goals through strategic consulting, executive advisory, and precision-led talent acquisition.
If you're:
• Transitioning from R&D to commercial operations
• Working toward FDA or CE approval
• Designing or executing go-to-market and market access strategies
• Advancing product development or planning clinical trial design and execution
• Strengthening the performance of your senior leadership team or board
I can help.
With 20+ years in professional staffing, I’ve personally delivered 400+ business-critical hires, and led teams responsible for 5,000+ successful placements globally.
I founded Hanison Green Ltd to support the most innovative neuromodulation companies in bringing breakthrough technologies to market; transforming the lives of patients suffering from chronic pain, movement disorders, and other neurological conditions.
What makes us different?
I operate solely within neuromodulation, and my team and I actively track over 350+ neurotech start-ups across the US & Europe. We offer deep market insight, a powerful leadership network, and the ability to identify and deliver the exact talent you need to overcome key growth challenges.
Our process is simple, targeted, and built around your business:
You give us the brief
We handle the full search, shortlist, process and offer
You stay focused on building your company
You get results
I operate as a true strategic partner; a trusted advisor, ambassador of your brand, and an extension of your team. I work with total professionalism, confidentiality, and commitment.
DM me to arrange a conversation; whether you’re hiring, scaling, or considering your own leadership career in neuromodulation.
I’m also co-founder of Recruitment Founders Club; a community and partnership that supports ambitious recruiters to launch and grow their own businesses. If you’ve been thinking about going solo, let’s talk.
I’m also proud to be co-founder of Touchdown Neurotech - a commercialisation consultancy helping US-based neurotech start-ups expand into Europe, the UK and the Middle East. At Touchdown, we support market analysis, go-to-market design, and real-world execution; helping the brightest innovators take their tech to patients globally..

